Literature DB >> 16368967

Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.

Zong Liang Chang1, Dale Netski, Peter Thorkildson, Thomas R Kozel.   

Abstract

Glucuronoxylomannan (GXM), the major component of the capsular polysaccharide of Cryptococcus neoformans, is essential to virulence of the yeast. Previous studies found that the interaction between GXM and phagocytic cells has biological consequences that may contribute to the pathogenesis of cryptococcosis. We found that GXM binds to and is taken up by murine peritoneal macrophages. Uptake is dose and time dependent. Examination of the sites of GXM accumulation by immunofluorescence microscopy showed that the pattern was discontinuous and punctate both on the surfaces of macrophages and at intracellular depots. Although resident macrophages showed appreciable accumulation of GXM, uptake was greatest with thioglycolate-elicited macrophages. A modest stimulation of GXM binding followed treatment of resident macrophages with phorbol 12-myristate 13-acetate, but treatment with lipopolysaccharide or gamma interferon alone or in combination had no effect. Accumulation of GXM was critically dependent on cytoskeleton function; a near complete blockade of accumulation followed treatment with inhibitors of actin. GXM accumulation by elicited macrophages was blocked by treatment with inhibitors of tyrosine kinase, protein kinase C, and phospholipase C, but not by inhibitors of phosphatidylinositol 3-kinase, suggesting a critical role for one or more signaling pathways in the macrophage response to GXM. Taken together, the results demonstrate that it is possible to experimentally enhance or suppress binding of GXM to macrophages, raising the possibility for regulation of the interaction between this essential virulence factor and binding sites on cells that are central to host resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368967      PMCID: PMC1346664          DOI: 10.1128/IAI.74.1.144-151.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes.

Authors:  A Vecchiarelli; C Retini; C Monari; C Tascini; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.

Authors:  N Lendvai; A Casadevall; Z Liang; D L Goldman; J Mukherjee; L Zuckier
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

3.  Interleukin-6 production by human monocytes stimulated with Cryptococcus neoformans components.

Authors:  D Delfino; L Cianci; E Lupis; A Celeste; M L Petrelli; F Curró; V Cusumano; G Teti
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule.

Authors:  S Shoham; C Huang; J M Chen; D T Golenbock; S M Levitz
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

5.  Cryptococcal glucuronoxylomannan induces interleukin (IL)-8 production by human microglia but inhibits neutrophil migration toward IL-8.

Authors:  M M Lipovsky; G Gekker; S Hu; L C Ehrlich; A I Hoepelman; P K Peterson
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

6.  Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils.

Authors:  C Retini; A Vecchiarelli; C Monari; C Tascini; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

7.  Cryptococcal polysaccharides bind to CD18 on human neutrophils.

Authors:  Z M Dong; J W Murphy
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

8.  Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice.

Authors:  N Lendvai; X W Qu; W Hsueh; A Casadevall
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

9.  Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis.

Authors:  A C Savoy; D M Lupan; P B Manalo; J S Roberts; A M Schlageter; L C Weinhold; T R Kozel
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

10.  Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network.

Authors:  R Cherniak; H Valafar; L C Morris; F Valafar
Journal:  Clin Diagn Lab Immunol       Date:  1998-03
View more
  15 in total

1.  Cryptococcus neoformans histone acetyltransferase Gcn5 regulates fungal adaptation to the host.

Authors:  Teresa R O'Meara; Christie Hay; Michael S Price; Steve Giles; J Andrew Alspaugh
Journal:  Eukaryot Cell       Date:  2010-06-25

Review 2.  How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts.

Authors:  Steven T Denham; Morgan A Wambaugh; Jessica C S Brown
Journal:  J Mol Biol       Date:  2019-05-09       Impact factor: 5.469

3.  Biochemical systems analysis of signaling pathways to understand fungal pathogenicity.

Authors:  Jacqueline Garcia; Kellie J Sims; John H Schwacke; Maurizio Del Poeta
Journal:  Methods Mol Biol       Date:  2011

4.  Glucuronoxylomannan from Cryptococcus neoformans down-regulates the enzyme 6-phosphofructo-1-kinase of macrophages.

Authors:  Juliana Grechi; Monica Marinho-Carvalho; Patricia Zancan; Leonardo Paes Cinelli; Andre M O Gomes; Marcio L Rodrigues; Leonardo Nimrichter; Mauro Sola-Penna
Journal:  J Biol Chem       Date:  2011-03-09       Impact factor: 5.157

5.  Enhanced innate immune responsiveness to pulmonary Cryptococcus neoformans infection is associated with resistance to progressive infection.

Authors:  Loïc Guillot; Scott F Carroll; Robert Homer; Salman T Qureshi
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

6.  Cryptococcus neoformans glucuronoxylomannan fractions of different molecular masses are functionally distinct.

Authors:  Priscila C Albuquerque; Fernanda L Fonseca; Fabianno F Dutra; Marcelo T Bozza; Susana Frases; Arturo Casadevall; Marcio L Rodrigues
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

7.  Contribution of the mannan backbone of cryptococcal glucuronoxylomannan and a glycolytic enzyme of Staphylococcus aureus to contact-mediated killing of Cryptococcus neoformans.

Authors:  Reiko Ikeda; Fumito Saito; Miki Matsuo; Kenji Kurokawa; Kazuhisa Sekimizu; Masashi Yamaguchi; Susumu Kawamoto
Journal:  J Bacteriol       Date:  2007-05-04       Impact factor: 3.490

Review 8.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

9.  Macrophage uptake, intracellular localization, and degradation of poly-gamma-D-glutamic acid, the capsular antigen of Bacillus anthracis.

Authors:  Marjorie D Sutherland; Thomas R Kozel
Journal:  Infect Immun       Date:  2008-11-10       Impact factor: 3.441

10.  Biology and function of exo-polysaccharides from human fungal pathogens.

Authors:  Krystal Y Chung; Jessica C S Brown
Journal:  Curr Clin Microbiol Rep       Date:  2020-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.